CytomX Therapeutics (CTMX) Common Equity: 2014-2025
Historic Common Equity for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $107.4 million.
- CytomX Therapeutics' Common Equity rose 557.91% to $107.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.4 million, marking a year-over-year increase of 557.91%. This contributed to the annual value of -$456,000 for FY2024, which is 99.04% up from last year.
- CytomX Therapeutics' Common Equity amounted to $107.4 million in Q3 2025, which was down 10.44% from $119.9 million recorded in Q2 2025.
- CytomX Therapeutics' Common Equity's 5-year high stood at $119.9 million during Q2 2025, with a 5-year trough of -$86.6 million in Q1 2023.
- Over the past 3 years, CytomX Therapeutics' median Common Equity value was -$31.2 million (recorded in 2024), while the average stood at -$9.5 million.
- Per our database at Business Quant, CytomX Therapeutics' Common Equity plummeted by 18,582.14% in 2022 and then skyrocketed by 557.91% in 2025.
- CytomX Therapeutics' Common Equity (Quarterly) stood at -$459,000 in 2021, then crashed by 18,582.14% to -$85.8 million in 2022, then surged by 44.67% to -$47.4 million in 2023, then spiked by 99.04% to -$456,000 in 2024, then soared by 557.91% to $107.4 million in 2025.
- Its Common Equity was $107.4 million in Q3 2025, compared to $119.9 million in Q2 2025 and $25.0 million in Q1 2025.